Section 1: Identification

Material

Simvastatin Tablets USP
5 mg, 10 mg, 20 mg, 40 mg and 80 mg

Manufacturer

Lupin Limited
MADE IN INDIA.

Distributor

Lupin Pharmaceuticals, Inc.
111 South Calvert Street,
Harborplace Tower, 21st Floor,
Baltimore, Maryland 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion

Expected to be non-combustible.

Health

Simvastatin is contraindicated in the following conditions:

- Concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products).
- Concomitant administration of gemfibrozil, cyclosporine, or danazol.
- Hypersensitivity to any component of this medication.
- Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.
- Women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Because HMG-CoA reductase inhibitors (statins) decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, simvastatin may cause fetal harm when administered to a pregnant woman.
- Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of use with simvastatin during pregnancy;
however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, simvastatin revealed no evidence of teratogenicity. **Simvastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive.** If the patient becomes pregnant while taking this drug, simvastatin should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus.

- Nursing mothers. It is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require treatment with simvastatin should not breastfeed their infants.

### Environment

No information is available about the potential of this product to produce adverse environmental effects.

---

## Section 3: Composition/Information on Ingredients

**Section 3, Composition/information on ingredients**

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simvastatin USP</td>
<td>79902-63-9</td>
</tr>
</tbody>
</table>

---

## Section 4: First-Aid Measures

### Section 4, First-aid measures

**Ingestion**

If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

**Inhalation**

Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

**Skin Contact**

Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

**Eye Contact**

Flush eyes with plenty of water. Get medical attention.

### NOTES TO HEALTH PROFESSIONALS

**Medical Treatment**

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.
OVERDOSAGE

Significant lethality was observed in mice after a single oral dose of 9 g/m². No evidence of lethality was observed in rats or dogs treated with doses of 30 and 100 g/m², respectively. No specific diagnostic signs were observed in rodents. At these doses the only signs seen in dogs were emesis and mucoid stools.

A few cases of overdosage with simvastatin have been reported; the maximum dose taken was 3.6 g. All patients recovered without sequelae. Supportive measures should be taken in the event of an overdose. The dialyzability of simvastatin and its metabolites in man is not known at present.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards
Assume that this product is capable of sustaining combustion.

Extinguishing Media
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures
For single units (packages): No special requirements needed.
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous Combustion Products
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

Section 6: Accidental Release Measures

Section 6, Accidental release measures

Personal Precautions
Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods
Collect and place it in a suitable, properly labeled container for recovery or disposal.

Section 7: Handling and Storage

Section 7, Handling and storage

Handling
No special control measures required for the normal handling of this product.
Normal room ventilation is expected to be adequate for routine handling of this product.
Storage
Store between 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Preserve in tight container as defined in USP.

Section 8: Exposure Controls/ Personal Protection

Section 8, Exposure controls/personal protection
Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form
Simvastatin tablets USP, 5 mg are tan colored, round, biconvex, film-coated tablets, debossed with ‘LL’ on one side and ‘C01’ on the other side. They are supplied as follows:

NDC 68180-482-06 Bottles of 30
NDC 68180-482-09 Bottles of 90
NDC 68180-482-03 Bottles of 1000

Simvastatin tablets USP, 10 mg are peach colored, oval shaped, biconvex, film-coated tablets, debossed with ‘LL’ on one side and ‘C02’ on the other side. They are supplied as follows:

NDC 68180-478-01 Bottles of 30
NDC 68180-478-02 Bottles of 90
NDC 68180-478-03 Bottles of 1000

Simvastatin tablets USP, 20 mg are tan colored, oval shaped, biconvex, film-coated tablets, debossed with ‘LL’ on one side and ‘C03’ on the other side. They are supplied as follows:

NDC 68180-479-01 Bottles of 30
NDC 68180-479-02 Bottles of 90
NDC 68180-479-03 Bottles of 1000

Simvastatin tablets USP, 40 mg are brick red colored, round shaped, biconvex, film-coated tablets, debossed with ‘LL’ on one side and ‘C04’ on the other side. They are supplied as follows:

NDC 68180-464-06 Bottles of 30
NDC 68180-464-09 Bottles of 90
NDC 68180-464-03 Bottles of 1000

Simvastatin tablets USP, 80 mg are brick red colored, capsule shaped, biconvex, film-coated tablets, debossed with ‘LL’ on one side and ‘C05’ on the other side. They are supplied as follows:

NDC 68180-465-06 Bottles of 30
NDC 68180-465-09 Bottles of 90
NDC 68180-465-03 Bottles of 1000
Section 10: Stability and Reactivity

Section 10, Stability and Reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively (as total inhibitory activity based on AUC) after an 80-mg oral dose. Liver carcinomas were significantly increased in high-dose females and mid- and high-dose males with a maximum incidence of 90% in males. The incidence of adenomas of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung adenomas in mid- and high-dose males and females. Adenomas of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day.

In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC). In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular adenomas in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC).

A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced hepatocellular adenomas and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell adenomas were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other statins. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80 milligram daily dose.

No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in an in vitro alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an in vitro chromosome aberration study in CHO cells, or an in vivo chromosomal aberration assay in mouse bone marrow.

There was decreased fertility in male rats treated with simvastatin for 34 weeks at 25 mg/kg body weight (4 times the maximum human exposure level, based on AUC, in patients receiving 80 mg/day); however, this effect was not observed during a subsequent fertility study in which simvastatin was administered at this same dose level to male rats for 11 weeks (the entire cycle of spermatogenesis including...
epididymal maturation). No microscopic changes were observed in the testes of rats from either study. At 180 mg/kg/day, (which produces exposure levels 22 times higher than those in humans taking 80 mg/day based on surface area, mg/m²), seminiferous tubule degeneration (necrosis and loss of spermatogenic epithelium) was observed. In dogs, there was drug-related testicular atrophy, decreased spermatogenesis, spermatocytic degeneration and giant cell formation at 10 mg/kg/day, (approximately 2 times the human exposure, based on AUC, at 80 mg/day). The clinical significance of these findings is unclear.

## Section 12: Ecological Information

No relevant studies identified.

## Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

## Section 14: Transport Information

### IATA/ICAO - Not Regulated

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IATA Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Packaging Group</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### IMDG - Not Regulated

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMDG Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Flash Point</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### DOT - Not Regulated

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOT Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Flash Point</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Packing Group</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.